Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.08 AUD
Change Today -0.002 / -2.38%
Volume 694.1K
ACW On Other Exchanges
Symbol
Exchange
Frankfurt
As of 1:34 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

actinogen ltd (ACW) Snapshot

Open
A$0.09
Previous Close
A$0.08
Day High
A$0.09
Day Low
A$0.08
52 Week High
04/21/15 - A$0.15
52 Week Low
06/24/14 - A$0.01
Market Cap
49.7M
Average Volume 10 Days
2.2M
EPS TTM
A$-0.0067
Shares Outstanding
606.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACTINOGEN LTD (ACW)

Related News

No related news articles were found.

actinogen ltd (ACW) Related Businessweek News

No Related Businessweek News Found

actinogen ltd (ACW) Details

Actinogen Limited discovers and isolates environmental bacteria known as the actinomycetes that are found in Western Australia. The company develops actinomycetes that produce plant growth hormones, shikimic acid, anacardic acid, and cellulase; and salt tolerant actinomycetes used to grow plants and crops in salt affected environments. Its products are applied in antibiotics and anti– fungal, anti-viral, and anti-cancer agents. Actinogen Limited is based in Sydney, Australia.

actinogen ltd (ACW) Top Compensated Officers

Chief Financial Officer
Total Annual Compensation: --
Compensation as of Fiscal Year 2013.

actinogen ltd (ACW) Key Developments

Actinogen Limited Announces Xanamem Advisory Board Appointments

Actinogen Limited announced the appointment of a powerhouse team of globally recognised leaders in Alzheimer's disease research to its Xanamem Advisory Board - Professor Craig Ritchie from Edinburgh UK, Professor Colin Masters from Melbourne Australia and Professor Jeff Cummings from the Cleveland Clinic USA. This Advisory Board has particular expertise in the early diagnosis and treatment of Alzheimer's disease and will help Actinogen Medical shape and drive the development of its new lead research drug, Xanamem. The Advisory Board will be chaired by Professor Craig Ritchie, Professor of Psychiatry of Ageing at the University of Edinburgh. Professor Ritchie is a leading authority on clinical trials in dementia and has been senior investigator on more than 30 drug trials of both disease-modifying and symptomatic agents for the condition. He has extensive knowledge of the industry, having sat on advisory boards of numerous pharmaceutical companies, biotechs and clinical research organizations with an in interest in developing drugs and trials infrastructure for Alzheimer's disease. Professor Colin Masters is currently the Executive Director of the Mental Health Research Institute, and a Laureate Professor at the University of Melbourne. He is also the Senior Deputy Director of the Florey Institute of Neuroscience and Mental Health, and a consultant at the Royal Melbourne Hospital. Professor Jeff Cummings is the Camille and Larry Ruvo Chair of the Neurological Institute of Cleveland Clinic and Professor of Medicine (Neurology), Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

Actinogen Limited. Reports Consolidated Earnings Results for the Half Year Ended December 31, 2014

Actinogen Limited. reported consolidated earnings results for the half year ended December 31, 2014. For the year, the company reported revenue from continuing operations of AUD 18,088 against AUD 20,000 a year ago. Loss before income tax was AUD 1,222,531 against AUD 153,242 a year ago. Loss for the year was AUD 1,222,531 against AUD 153,242 a year ago. Dilutive loss per share was 0.44 cents against 0.10 cents a year ago. Net cash outflow from operating activities was AUD 751,084 against AUD 119,735 a year ago. Purchase of property, plant and equipment was AUD 4,331 against AUD 5,252 a year ago.

Actinogen Medical Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

Actinogen Medical Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACW:AU A$0.08 AUD -0.002

ACW Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACW.
View Industry Companies
 

Industry Analysis

ACW

Industry Average

Valuation ACW Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 160.9x
Price/Book 4.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 330.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTINOGEN LTD, please visit www.actinogen.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.